- Cell-based therapeutics developer ReNeuron said that it presented positive efficacy data over the weekend at a conference in San Francisco.

The data, from the company's Phase 1/2a clinicla rial of its hRPC stem cell therapy in retinitis pigmentosa, was presented at the American Academy of Ophthalmology annual meeting.

Story provided by